Increased visfatin concentrations in women with gestational diabetes mellitus

Krzyżanowska, Katarzyna; Krugluger, Walter; Mittermayer, Friedrich; Rahman, R. Abdul; Haider, Dominik G.; Shnawa, N.; Schernthaner, Guntram

doi:10.1042/cs20050363

Cited by 155 publications

(152 citation statements)

References 26 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Therefore, mathematical models (HOMA vs IRI) used to calculate IR indices in pregnancy may give discrepant results, and thereby a relationship between visfatin and calculated IR indices. Very recently, unlike our findings and those by Krzyzanowska et al [9], Chan et al [10] have reported lower visfatin levels in women of Chinese origin with GDM. The precise reason for these differences is unclear.…”

Section: Discussioncontrasting

confidence: 98%

See 1 more Smart Citation

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis Concentrations of visfatin are increased in insulin-resistant conditions, but the relationship between visfatin and insulin and/or insulin resistance indices in pregnancy remains unclear. Insulin resistance in pregnancy is further accentuated in women with gestational diabetes mellitus (GDM). Thus we assessed serum levels of visfatin in pregnant women with varying degrees of glucose tolerance. Materials and methods Fasting visfatin levels were measured at 28 weeks of gestation in 51 women divided according to their response to a 50-g glucose challenge test (GCT) and a 75-g OGTT: control subjects (n=20) had normal responses to both a GCT and an OGTT; the intermediate group (IG; n=15) had a false-positive GCT, but a normal OGTT; the GDM group (n=16) had abnormal GCTs and OGTTs. Results There were no age or BMI differences between analysed groups. Across the subgroups there was a progressive increase in glucose and insulin at 120 min of the OGTT (p<0.01). This was accompanied by an increase in visfatin, from 76.8±14.1 ng/ml in the control subjects, to 84.0±14.7 ng/ml in the IG group and 93.1±12.3 ng/ml in the GDM group (p<0.01 for GDM vs control subjects). There was a positive correlation between visfatin and fasting insulin (r=0.38, p=0.007) and insulin at 120 min of the OGTT (r=0.39, p=0.006). Conclusions/interpretation An increase in fasting visfatin, the levels of which correlate with both fasting and postglucose-load insulin concentrations, accompanies worsening glucose tolerance in the third trimester of pregnancy. However, the significance of these findings, and in particular the role of visfatin in the regulation of insulin sensitivity during pregnancy, remains to be elucidated.

show abstract

Section: Discussioncontrasting

confidence: 98%

“…During the preparation of our paper, Krzyzanowska et al [9] reported raised visfatin levels in GDM. In contrast to their data, we found a significant correlation between visfatin and fasting insulin and HOMA.…”

Section: Discussionmentioning

confidence: 84%

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The number of participants, gestational age at enrolment, BMI, and the specificity of the immunoassays applied differ between all the above studies. Gestational diabetes mellitus is a state of temporary insulin resistance, and elevated visfatin concentrations might counteract high glucose and insulin levels [52]. Thus, elevated maternal visfatin concentrations in GDM at 2nd trimester may reflect an impairment of visfatin function in target tissues, dysregulation of biosynthesis, or a response to hyperglycemia [52].…”

Section: Discussionmentioning

confidence: 99%

“…Gestational diabetes mellitus is a state of temporary insulin resistance, and elevated visfatin concentrations might counteract high glucose and insulin levels [52]. Thus, elevated maternal visfatin concentrations in GDM at 2nd trimester may reflect an impairment of visfatin function in target tissues, dysregulation of biosynthesis, or a response to hyperglycemia [52]. On the other hand, TNF-a is known to enhance visfatin expression in human placental cells [53].…”

Section: Discussionmentioning

confidence: 99%

Maternal Leptin, Adiponectin, Resistin, Visfatin and Tumor Necrosis Factor-Alpha in Normal and Gestational Diabetes

Noureldeen

Qusti²,

Al‐Seeni³

et al. 2013

Ind J Clin Biochem

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a common medical complication associated with pregnancy. The present study evaluates the changes in maternal adipocytokines (leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha; TNF-a) in pregnancy complicated with GDM compared to normal pregnancy at 2nd and 3rd trimesters. The study included total number of 142 pregnant women classified into 4 groups: normal pregnancy (n = 33) and pregnancy with GDM (n = 24) both at 2nd trimester and normal pregnancy (n = 38) and GDM (n = 47) at 3rd trimester. Both GDM groups were significantly presented with elevated body mass index, fasting blood sugar and abnormal oral glucose tolerance test compared to their matched control. Results indicated reduction in maternal serum leptin and adiponectin in GDM compared to normal pregnancy at 3rd trimester. Elevated resistin and TNF-a were evident among pregnancy complicated with GDM at both tested trimesters. On the other hand, significant elevation in maternal visfatin was noted between GDM and matched control at 2nd trimester only. Significant increase in maternal leptin and visfatin and resistin was noted by advances in gestational period in healthy pregnancy. On the other hand, reduced adiponectin and elevated visfatin mean values were noticed in GDM at 3rd compared to 2nd trimester. It could be concluded that increased insulin resistance accompanies GDM is associated with suppressed leptin and adiponectin and increased resistin and TNF-a which might suggest their involvement in the development of GDM.

show abstract

“…Data available on visfatin levels in patients with GDM are also controversial. To date, two previous studies (11,12) reported increased visfatin concentrations in GDM, whereas others (13,14) showed that GDM is associated with decreased visfatin concentrations. Since visfatin is an adipocytokine that is associated with glucose homeostasis, we hypothesized that maternal visfatin concentrations might be altered in pregnant women with GDM in the third trimester, which is an advanced state of insulin resistance.…”

Section: Introductionmentioning

confidence: 96%

Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

Aktürk

Altınova

Mert

et al. 2008

J Endocrinol Invest

View full text Add to dashboard Cite

ABSTRACT. Our aim is to investigate visfatin concentration and its relationship to glycated hemoglobin (HbA 1c ), insulin resistance, lipid parameters, and neonatal birth weight in women with gestational diabetes mellitus (GDM). In our study group, there were 47 women with GDM and 31 women with normal glucose tolerance (NGT) between 33-39 weeks of gestation. Plasma visfatin levels were significantly decreased in pregnant women with GDM compared to those with NGT (p=0.001). Homeostasis model assessmentinsulin resistance (HOMA-IR) levels were higher in the GDM group than in the NGT group (p=0.006). In all subjects, plasma visfatin levels were negatively correlated with HOMA-IR, post-prandial blood glucose, triglycerides, and VLDL cholesterol (p<0.05). We did not observe any statistically significant correlation between the plasma visfatin levels and the selected parameters in the GDM group, but in the NGT group plasma visfatin levels were negatively correlated with HOMA-IR (r=-0.36, p=0.04). There was no correlation between visfatin concentrations and fetal birth weight in either group (p>0.05). By regression analysis, having GDM was found to be the only significant determinant (t=3.5, p=0.001) of visfatin concentration (R=0.39, r 2 =0.15). We conclude that women with GDM have significantly decreased visfatin concentrations in the third trimester. Future studies are required to establish the exact role of visfatin in the pathogenesis of GDM. (J. Endocrinol. Invest. 31: 610-613, 2008)

show abstract

Increased visfatin concentrations in women with gestational diabetes mellitus

Cited by 155 publications

References 26 publications

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Maternal Leptin, Adiponectin, Resistin, Visfatin and Tumor Necrosis Factor-Alpha in Normal and Gestational Diabetes

Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

Contact Info

Product

Resources

About